Literature DB >> 22969859

Suppression of HIF-1α expression and radiation resistance in acute hypoxic conditions.

Takahiro Oike1, Yoshiyuki Suzuki, Wael Al-Jahdari, Abdulelah Mobaraki, Jun-Ichi Saitoh, Kohta Torikai, Katsuyuki Shirai, Takashi Nakano.   

Abstract

Recently, it has become clear that acute hypoxia affecting radioresistance exists widely in tumor tissues. Concurrently, hypoxia-inducible factor-1α (HIF-1α) is recognized as an essential transcriptional factor, enabling cells to survive through hypoxia. However, it is unclear as to whether HIF-1α plays a direct role in the radioresistance caused by acute hypoxia. Therefore, in this study, we investigated the in vitro response of the human lung adenocarcinoma cell line, A549, to ionizing radiation in an experimental model that imitates acute hypoxia in the presence and absence of HIF-1α expression, using the HIF-1α inhibitor 5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol (YC-1). Cells were treated with or without 10 μM YC-1 for 2 h. Cells were exposed to either 95% N(2) and 5% CO(2) (hypoxic condition of <0.1 mmHg) or atmospheric air (normoxic condition) for 1 h, and irradiated with 2, 5 and 10 Gy. Western blot analysis revealed that, without YC-1, cells exposed to hypoxic conditions expressed increased levels of HIF-1α compared with those exposed to normoxic conditions. Under hypoxic conditions, HIF-1α expression was suppressed by YC-1 to the same extent as that observed in cells exposed to normoxic conditions without YC-1. Clonogenic survival assay revealed that under hypoxic conditions there was no significant difference between the surviving fraction of cells treated with YC-1 and without YC-1 at any dose point examined. The oxygen enhancement ratio at 10% surviving fraction was calculated as 2.7 and 2.6 in the presence and the absence of YC-1, respectively. These results indicate that HIF-1α itself is not an immediate cause of acute hypoxia-induced radioresistance in A549 cells.

Entities:  

Year:  2011        PMID: 22969859      PMCID: PMC3438631          DOI: 10.3892/etm.2011.373

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis.

Authors:  P Birner; B Gatterbauer; G Oberhuber; M Schindl; K Rössler; A Prodinger; H Budka; J A Hainfellner
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

3.  Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy.

Authors:  R A Gatenby; H B Kessler; J S Rosenblum; L R Coia; P J Moldofsky; W H Hartz; G J Broder
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-05       Impact factor: 7.038

4.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck.

Authors:  M Nordsmark; M Overgaard; J Overgaard
Journal:  Radiother Oncol       Date:  1996-10       Impact factor: 6.280

5.  Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Authors:  R Bos; H Zhong; C F Hanrahan; E C Mommers; G L Semenza; H M Pinedo; M D Abeloff; J W Simons; P J van Diest; E van der Wall
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

7.  Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: accuracy and reproducibility.

Authors:  K A Yeh; S Biade; R M Lanciano; D Q Brown; M C Fenning; J S Babb; G E Hanks; D C Chapman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-08-30       Impact factor: 7.038

8.  The pervasive presence of fluctuating oxygenation in tumors.

Authors:  Laura I Cárdenas-Navia; Daniel Mace; Rachel A Richardson; David F Wilson; Siqing Shan; Mark W Dewhirst
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

9.  The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts.

Authors:  Hiroshi Harada; Shinae Kizaka-Kondoh; Satoshi Itasaka; Keiko Shibuya; Akiyo Morinibu; Kazumi Shinomiya; Masahiro Hiraoka
Journal:  Biochem Biophys Res Commun       Date:  2007-07-05       Impact factor: 3.575

10.  Transient perfusion in human melanoma xenografts.

Authors:  I Tufto; E K Rofstad
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more
  5 in total

1.  The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy.

Authors:  Blake R Smith; Nicholas P Nelson; Theodore J Geoghegan; Kaustubh A Patwardhan; Patrick M Hill; Jen Yu; Alonso N Gutiérrez; Bryan G Allen; Daniel E Hyer
Journal:  Med Phys       Date:  2022-02-21       Impact factor: 4.071

2.  Digoxin downregulates NDRG1 and VEGF through the inhibition of HIF-1α under hypoxic conditions in human lung adenocarcinoma A549 cells.

Authors:  Dong Wei; Jing-Jing Peng; Hui Gao; Hua Li; Dong Li; Yong Tan; Tao Zhang
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

3.  Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions.

Authors:  Hiroki Ushijima; Yoshiyuki Suzuki; Takahiro Oike; Mayumi Komachi; Yuya Yoshimoto; Ken Ando; Noriyuki Okonogi; Hiro Sato; Shin-Ei Noda; Jun-Ichi Saito; Takashi Nakano
Journal:  J Radiat Res       Date:  2015-04-16       Impact factor: 2.724

Review 4.  Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma.

Authors:  Zhuo Chen; Xin-Hua Xu
Journal:  Saudi Med J       Date:  2015-06       Impact factor: 1.484

5.  The relationship between the preoperative plasma level of HIF-1α and clinic pathological features, prognosis in non-small cell lung cancer.

Authors:  Jiabei He; Ying Hu; Mingming Hu; Siyi Zhang; Baolan Li
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.